HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marina K Cugliari Selected Research

HAD protocol

1/2022Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marina K Cugliari Research Topics

Disease

1Inflammation (Inflammations)
07/2022
1Melanoma (Melanoma, Malignant)
01/2022
1Neoplasms (Cancer)
01/2022

Drug/Important Bio-Agent (IBA)

1Capsules (Microcapsules)IBA
07/2022
1NivolumabIBA
01/2022
1IpilimumabIBA
01/2022

Therapy/Procedure

1Immunotherapy
01/2022
1HAD protocol
01/2022
1Therapeutics
01/2022